Roman Butler Fullerton & Co. Invests $558,000 in Exelixis, Inc. $EXEL

Roman Butler Fullerton & Co. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 14,156 shares of the biotechnology company’s stock, valued at approximately $558,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Plato Investment Management Ltd raised its holdings in shares of Exelixis by 52.5% during the third quarter. Plato Investment Management Ltd now owns 9,417 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 3,243 shares during the last quarter. Alps Advisors Inc. increased its position in Exelixis by 18.5% in the 3rd quarter. Alps Advisors Inc. now owns 11,651 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 1,823 shares during the period. Axim Planning & Wealth acquired a new stake in Exelixis in the 3rd quarter valued at approximately $901,000. MONECO Advisors LLC raised its stake in Exelixis by 25.0% during the 3rd quarter. MONECO Advisors LLC now owns 6,146 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 1,228 shares in the last quarter. Finally, Castlekeep Investment Advisors LLC boosted its position in Exelixis by 25.1% during the 3rd quarter. Castlekeep Investment Advisors LLC now owns 39,411 shares of the biotechnology company’s stock worth $1,628,000 after acquiring an additional 7,919 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of EXEL opened at $43.95 on Tuesday. The company has a 50-day moving average of $43.70 and a two-hundred day moving average of $40.94. The stock has a market cap of $11.78 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 0.74 and a beta of 0.42. Exelixis, Inc. has a one year low of $32.38 and a one year high of $49.62.

Insider Buying and Selling

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 34,187 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $41.88, for a total transaction of $1,431,751.56. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 172,230 shares of company stock valued at $7,401,923 in the last ninety days. Company insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EXEL shares. Truist Financial set a $51.00 price objective on shares of Exelixis in a research note on Wednesday, January 14th. Zacks Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Wolfe Research assumed coverage on shares of Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. TD Cowen reiterated a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Finally, Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $46.16.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.